| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The specific molecular targets of 6-(4-methoxyphenyl)pyridazin-3-amine have not been identified in the published literature. As a pyridazine derivative, compounds in this class may interact with various enzymes, receptors, or ion channels depending on their substitution patterns. The compound is primarily used as a chemical intermediate or research chemical rather than a characterized pharmacological agent. Further studies would be needed to identify specific protein targets.
|
|---|---|
| ln Vitro |
In vitro activity data for 6-(4-methoxyphenyl)pyridazin-3-amine are not available in the published literature. As a pyridazine derivative, the compound may be evaluated in standard screening assays for potential biological activities including antimicrobial susceptibility testing, cytotoxicity screening in cancer cell lines, or enzyme inhibition assays. However, specific activity data for this compound have not been reported.
|
| ln Vivo |
In vivo activity data for 6-(4-methoxyphenyl)pyridazin-3-amine are not available in the published literature. The compound has not been studied in animal models for therapeutic applications. As a research chemical, its primary applications are likely in chemical synthesis and as a reference standard.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 6-(4-methoxyphenyl)pyridazin-3-amine would depend on the specific biological activity being investigated. Standard assay systems could include receptor binding assays for various targets, enzyme inhibition assays, or antimicrobial susceptibility testing. However, specific assay protocols for this compound have not been reported in the literature. The compound would be tested at concentrations typically ranging from 1-100 μM.
|
| Cell Assay |
Cellular assays for 6-(4-methoxyphenyl)pyridazin-3-amine would be performed using appropriate cell lines depending on the biological activity being investigated. Standard cell lines for screening could include cancer cell lines for cytotoxicity assessment, macrophage cell lines for anti-inflammatory activity, or bacterial cultures for antimicrobial testing. Cells would be cultured in appropriate media and treated with compound at various concentrations for 24-72 hours.
|
| Animal Protocol |
In vivo animal studies for 6-(4-methoxyphenyl)pyridazin-3-amine are not documented in the published literature. The compound has not been studied in animal models. Any potential in vivo studies would depend on the identification of specific biological activities in vitro that warrant further investigation.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for 6-(4-methoxyphenyl)pyridazin-3-amine are not available in the published literature. As a small molecule with a pyridazine core and methoxyphenyl substitution, the compound would be expected to have moderate lipophilicity and potentially favorable oral bioavailability. Standard pharmacokinetic studies would be needed to determine absorption, distribution, metabolism, and elimination characteristics.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 6-(4-methoxyphenyl)pyridazin-3-amine are not available in the published literature. As a research chemical, standard toxicological characterization would be required for any therapeutic development. The compound should be handled with standard laboratory safety precautions. It is not approved for human therapeutic use.
|
| References |
[1]. Wermuth CG, et al. Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of gamma-aminobutyric acid acting as selective GABA-A antagonists. J Med Chem. 1987 Feb;30(2):239-49.
|
| Additional Infomation |
6-(4-Methoxyphenyl)pyridazin-3-amine is a pyridazine derivative used as a research chemical. The compound features a pyridazine ring with a 4-methoxyphenyl substituent at the 6-position and an amino group at the 3-position. As a pyridazine-containing compound, it may have potential applications in medicinal chemistry. The compound is not currently approved for clinical use; all applications remain at the research stage.
|
| Molecular Formula |
C11H11N3O
|
|---|---|
| Molecular Weight |
201.22
|
| Exact Mass |
201.09
|
| CAS # |
4776-87-8
|
| PubChem CID |
13735353
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.51 g/cm3
|
| Boiling Point |
432.957 °C at 760 mmHg
|
| Index of Refraction |
1.677
|
| LogP |
2.315
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
15
|
| Complexity |
192
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)C2=NNC(=N)C=C2
|
| InChi Key |
PCPMUYYPWJFHEQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H11N3O/c1-15-9-4-2-8(3-5-9)10-6-7-11(12)14-13-10/h2-7H,1H3,(H2,12,14)
|
| Chemical Name |
6-(4-methoxyphenyl)pyridazin-3-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9697 mL | 24.8484 mL | 49.6968 mL | |
| 5 mM | 0.9939 mL | 4.9697 mL | 9.9394 mL | |
| 10 mM | 0.4970 mL | 2.4848 mL | 4.9697 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
